This website uses cookies to provide you with the best experience. By using this site you agree to our use of cookies. Please read our cookie notice for more information.

« Back

ICON Announces Appointment of Cathrin Petty to Board of Directors

October 26, 2010

DUBLIN, Oct 26, 2010 (BUSINESS WIRE) -- ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Cathrin Petty as a non-executive Director. Cathrin was appointed unanimously by ICON's board of directors and, in accordance with the company's Articles of Association, will stand for re-election by ICON's shareholders at the Company's next annual general meeting.

Cathrin is a Special Partner at Vitruvian Partners LLP and also serves as a Non Executive Director for the NHS (Strategic Health Authority for Greater London), a Non Executive Director for Circassia Ltd and an advisor to Merz Pharma GmBH

Between 2000 and 2010 Cathrin was a Healthcare Partner in Apex Partners LLP with responsibility for originating, executing, monitoring and exiting healthcare private equity investments with a specific focus on Life Science investments in the pharmaceutical and medical device arena. Her early career included Senior Associate and Research Analyst roles at Schroder Ventures Life Sciences and Schroders Investment Management.

"We are delighted to welcome Cathrin to the ICON Board," commented Chairman, Dr. Bruce Given. "Her financial experience, coupled with her extensive expertise in the analysis of healthcare industry trends, strategies and financial performance will complement the strengths and talents of our existing board members."

Notes to Editors:

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,700 employees, operating from 71 offices in 39 countries.



ICON plc
Emily Brand
Corporate Communications Manager

Copyright Business Wire 2010

Search Investor